Drug Search Results
Using advanced filters...
Advanced Search [+]

Fezakinumab

Alternative Names: fezakinumab, ilv-094
Latest Update: 2024-08-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: IL22 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid|Dermatitis, Atopic

Phase 1: Healthy Volunteers|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JKR-0766

P2

Completed

Dermatitis, Atopic

2016-02-01

3199K1-2001

P2

Completed

Arthritis, Rheumatoid

2011-02-18

2008-006936-37

P2

Completed

Arthritis, Rheumatoid

2011-02-18

JapicCTI-101247

P2

Completed

Arthritis, Rheumatoid

2011-02-18

Recent News Events